For qualified non-clinical research buyers, including independent researchers, educators, analysts and research teams. Not for human or veterinary use.

Research evidence guide

GHRP-2 and GHRP-6: compare identities before assays.

A cited buyer guide to two distinct hexapeptides, GHSR1a assay evidence, model-specific limitations and current non-clinical research formats.

Evidence snapshotGHRP-2 and GHRP-6 are distinct synthetic hexapeptides with different chemical structures. A family name or shared assay target does not make their identities, activities or seller materials interchangeable.[1][2][3]

Compare current prices and formats.

For qualified non-clinical research buyers. Not for human or veterinary use.

Disclosure: We may earn a commission from purchases made through our links.

Two names, two chemical identities

PubChem identifies GHRP-2 as pralmorelin (CID 6918245; molecular formula C45H55N9O6) and records GHRP-6 separately as CID 4345065 (molecular formula C46H56N12O6).[1][2] These database records establish reference structures, not the identity, salt or counterion, quantity basis, purity, stability or performance of a seller lot.

Chemical database evidenceStructure records are useful identity references.[1][2] They do not authenticate the material received by a laboratory.
Family-level terminologyBoth names appear within the synthetic growth-hormone-releasing peptide literature. That shared family label does not support substitution between the two compounds or between studies.

GHSR1a binding is an assay result, not complete equivalence

A 2017 structure–activity study used a radiocompetitive assay against radioactive ghrelin to examine binding at GHSR1a for several intact GHRPs and related metabolites, including GHRP-2 and GHRP-6.[3] The work supports assay-specific comparison across a defined test system. It does not establish equal potency across methods, comprehensive selectivity, organism-level outcomes or the properties of a commercial material.

Evidence boundary: chemical structures, membrane binding, engineered-cell signaling, primary-cell release assays and animal experiments answer different questions. Results should remain attached to the material, model, endpoint and conditions actually studied.

Comparative experiments depend on model and endpoint

A 1998 study compared GHRP-2 and GHRP-6 alongside ipamorelin in primary rat pituitary cells and animal experiments. The reported relative potency and efficacy varied with the system and measured endpoint.[4] Those experiments can inform model selection; they are not a basis for a human-use claim or for assuming that two seller listings are experimentally interchangeable.

Binding-site and signaling studies add different layers

A human-tissue membrane study used radiolabeled Tyr-Ala-hexarelin and found that unlabeled synthetic secretagogues, including GHRP-2 and GHRP-6, displaced binding in pituitary and hypothalamic membrane preparations.[5] A separate GHRP-6 study used infant-rat anterior pituitary cultures and engineered HEK293 cells expressing the secretagogue receptor to investigate transcriptional signaling.[6] Tissue binding and engineered-cell signaling are distinct evidence types and neither authenticates a seller lot.

Off-target conclusions must stay panel-limited

A 1997 receptor-panel experiment examined GHRP-6 at four human melanocortin receptor subtypes in a transient-expression cell system and reported low-affinity observations at MC1 and MC5.[7] This does not establish a comprehensive selectivity profile, and it provides no direct evidence about GHRP-2. Procurement teams should avoid turning one limited panel into a broad “selective” or “nonselective” label.

Procurement checks for GHRP-2 and GHRP-6

  • Match the requested compound to the exact name and reference structure; do not order by the family acronym alone.
  • Record the documented sequence or structure, stereochemistry, termini, salt or counterion, quantity basis and formulation when supplied.
  • Match current lot documentation to the exact listing and received lot; literature and database records are not lot evidence.
  • Define the receptor construct, assay format, controls, matrix, endpoint and acceptance criteria in the laboratory protocol.
  • Check current seller price, availability, shipping eligibility, fulfillment terms and institutional receiving controls before ordering.

Review current research formats

The cards below use current seller-catalog title, format, price and availability facts retrieved during generation. The literature above does not establish the identity, quality, purity, stability, performance or results of either seller product.

Sources

  1. PubChem Compound Summary: Pralmorelin, CID 6918245 — GHRP-2 structure-level chemical database record.
  2. PubChem Compound Summary: GHRP-6, CID 4345065 — GHRP-6 structure-level chemical database record.
  3. Structure-activity relationship for peptidic growth hormone secretagogues — radiocompetitive GHSR1a assay study.
  4. Ipamorelin, the first selective growth hormone secretagogue — primary rat-pituitary and animal-model comparison including GHRP-2 and GHRP-6.
  5. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland — human-tissue membrane-binding study.
  6. Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor — rat primary-cell and engineered-cell signaling study.
  7. Characterization of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes — limited receptor-panel binding study.